Lonza to acquire five Merck KGaA US facilities, more than doubling its US footprint

Lonza, a Swiss contract development and manufacturing organization, announced it will purchase five U.S. manufacturing sites from Merck KGaA.

The transaction is valued in the low‑ to mid‑triple‑digit million Swiss‑franc range, with the CEO estimating a price between CHF 100 million and CHF 600 million.

The acquired plants include a bioconjugation facility in St. Louis, high‑potency payload‑linker sites in Madison and Verona, Wisconsin, and a viral‑vector plant in Car… These assets will expand Lonza’s capabilities in antibody‑drug conjugates and viral vectors, complementing its existing ADC site in Visp, Switzerland.

William Blair analysts said the deal strengthens Lonza’s competitive position in high‑growth modalities and supports its next growth phase.